Literature DB >> 2115538

Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking.

J T Rivers1, H D White, D B Cross, B F Williams, R M Norris.   

Abstract

A group of 456 consecutive patients seen less than or equal to 6 h after the onset of acute myocardial infarction associated with ST segment elevation received thrombolytic therapy and were followed up for 12 months. Intravenous streptokinase was given to 315 patients and recombinant tissue-type plasminogen activator (rt-PA) to 141 patients. Reinfarction rate and risk factors for reinfarction were assessed. Management after thrombolysis was conservative; revascularization procedures were reserved for patients with symptoms refractory to medical therapy or for those with left main coronary artery stenosis. Coronary artery surgery or angioplasty was performed in only 3.7% of patients during the first 30 days after thrombolysis and in only 8.6% by 1 year. Most patients (79%) underwent coronary arteriography. Twenty-six patients (5.7%) exhibited signs of threatened reinfarction at 1 month after thrombolytic therapy as did 43 patients (9.4%) by 1 year. Reinfarction was prevented in four of these patients by early readministration of thrombolytic therapy. Multivariate analysis of possible risk factors for reinfarction identified at the time of initial infarction showed current cigarette smoking to be the only predictive factor (reinfarction occurred in 12.5% of smokers versus 6.3% of nonsmokers, p = 0.04). A second analysis of risk factors identified 3 weeks after initial infarction, including the severity of residual stenosis at coronary arteriography and exercise test variables, again showed continued cigarette smoking to be the only factor predictive of reinfarction. Twenty percent of patients who continued to smoke developed reinfarction compared with 5.1% of those who stopped (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2115538     DOI: 10.1016/0735-1097(90)90583-b

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

1.  Immunoglobulin response to intravenous streptokinase in acute myocardial infarction.

Authors:  S C Grant
Journal:  Br Heart J       Date:  1992-05

2.  Thrombolytic treatment for recurrent myocardial infarction.

Authors:  H White
Journal:  BMJ       Date:  1991-02-23

3.  Prognostic value of predischarge radionuclide ventriculography at rest and exercise after acute myocardial infarction treated with thrombolytic therapy or primary coronary angioplasty. The Zwolle Myocardial Infarction Study Group.

Authors:  A T Gosselink; A L Liem; S Reiffers; F Zijlstra
Journal:  Clin Cardiol       Date:  1998-04       Impact factor: 2.882

Review 4.  Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?

Authors:  J Brügemann; P A de Graeff; J van der Meer; K I Lie
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

5.  Antibodies to streptokinase.

Authors:  K Jennings
Journal:  BMJ       Date:  1996-02-17

6.  Are streptokinase antibodies clinically important?

Authors:  H S Lee; S J Cross; K Jennings
Journal:  Br Heart J       Date:  1993-12

7.  Streptokinase neutralisation titres up to 866 days after intravenous streptokinase for acute myocardial infarction.

Authors:  S Patel; S Jalihal; D P Dutka; G K Morris
Journal:  Br Heart J       Date:  1993-08

8.  Safety of thrombolytic treatment in patients with central venous cannulation.

Authors:  H S Lee; T Quinn; R M Boyle
Journal:  Br Heart J       Date:  1995-04

Review 9.  The benefits of stopping smoking and the role of nicotine replacement therapy in older patients.

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

Review 10.  Comparative tolerability profiles of thrombolytic agents. A review.

Authors:  K S Woo; H D White
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.